Replies to post #677264 on NorthWest Biotherapeutics Inc (NWBO)

[Single Stock]

Mulholland presented at NYAS .. that's why I thought it was DCVAX .. but missed the ipilimumab

[learningcurve2020]

Wow!!! What a mindless blowoff of an extremely relevant article. Just can't make it up. Geez.

[exwannabe]

Unfortunately for Dr Mullholand his IPI-GLIO failed failed because the SOC arm did so well.

Overall Survival (Arm A vs B): median OS 22.7 vs 26.4 months, HR 1.223 (60% CI 0.986-1.516, p=0.431); 18 month OS 53% (60%CI 48-58%) vs 64% (56-70%).

Maybe the problem in his trial was that after the SOC patients progressed they elected to usu Yervoy on their own. Yea, that must be it.

Truly amazing how again and again we see trials where the randomized comparison fails but a comp to ECA's would indicate success.

[norisknorewards]

good catch.

FeMike, you cool with that?

[Single Stock]

Ipilimumab is Yervoy ( BMY ) according to Bard and was approved in 2011 for late stage melanoma ?

and says :

Ipilimumab is currently being investigated in phase II clinical trials for GBM.

Ipilimumab is not currently approved as a standard treatment for Glioblastoma (GBM) in either the USA or UK. While it has shown promise in pre-clinical studies and is being investigated in clinical trials, it has not yet gone through the full approval process for GBM.

Here's some additional information:

Ipilimumab works by targeting a specific part of the immune system, and its effectiveness for GBM is still under research.
Clinical trials are ongoing to assess its safety and efficacy for GBM treatment, either alone or combined with other therapies.
You can find more details about clinical trials involving Ipilimumab and GBM on resources like https://clinicaltrials.gov/.